Articles > Popular publications > PR Newswire press releases > April-June 2007 > Tuesday, April 17

Article: CERVARIX(R), GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years.

Article from:
PR Newswire
Article date:
April 17, 2007
Copyright

New study results also show evidence of additional protection against infection with other cancer-causing virus types

LOS ANGELES, April 17 /PRNewswire-FirstCall/ -- The GlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R), demonstrated 100 percent efficacy in preventing precancerous lesions due to cancer-causing human papillomavirus types 16 and 18 for up to 5.5 years in an extended follow-up trial, according to data presented today at the American Association for Cancer Research. The trial results demonstrate the longest duration of protection seen in any cervical cancer vaccine trial reported to date.

The GSK cervical cancer candidate ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: Mathematical Model Based on Clinical Findings From Cervarix(TM), ...

  
  PR Newswire; 
  October 30, 2006 ;  
  
  
 
  700+ words
... ... TM), GSK's cervical cancer candidate vaccine, has the potential ... vaccination with GSK's cervical cancer candidate vaccine -- which has shown ... evidence that GSK's cervical cancer candidate vaccine has been shown to ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: New Data Show Cervarix(TM), GSK's HPV 16/18 Cervical ...

  
  PR Newswire; 
  June 5, 2006 ;  
  
  
 
  700+ words
... ... and LSE: GSK] cervical cancer candidate vaccine is highly immunogenic ... vaccinated with GSK's cervical cancer candidate vaccine demonstrated antibody ... infection. GSK's cervical cancer candidate vaccine is formulated with ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: GSK Cervical Cancer Candidate Vaccine ...

  
  PR Newswire; 
  March 10, 2008 ;  
  
  
 
  700+ words
... ... GlaxoSmithKline's cervical cancer candidate vaccine, CERVARIX(R ... this time, the cervical cancer candidate vaccine showed 100 percent ... study of GSK's cervical cancer candidate vaccine. The initial study ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: CERVARIX(R), the GSK Cervical Cancer ...

  
  PR Newswire; 
  June 5, 2007 ;  
  
  
 
  700+ words
... ... GlaxoSmithKline (GSK) cervical cancer candidate vaccine had antibodies present ... doses of the GSK cervical cancer candidate vaccine at 0, 1 and 6 months ... About the GSK cervical cancer candidate vaccine GSK submitted a ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc. and ...

  
  M2 Presswire; 
  October 31, 2006 ;  
  
  
 
  700+ words
... ... from Cervarix, GSK's Cervical Cancer Candidate Vaccine, Suggests Vaccination ... GSK's (NYSE:GSK) cervical cancer candidate vaccine, has the potential to reduce the incidence of cervical cancer by up to 80%, based ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Cervarix(TM), GSK's Candidate Vaccine for ...

  
  PR Newswire; 
  April 5, 2006 ;  
  
  
 
  700+ words
... ... GlaxoSmithKline's (GSK) candidate vaccine for cervical cancer prevention, showed ... globally. GSK's candidate vaccine for cervical cancer is formulated ... developed this candidate vaccine for cervical cancer with the ambition ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: GlaxoSmithKline Initiates Head-to-Head Study of Cervical ...

  
  PR Newswire Europe; 
  January 18, 2007 ;  
  
  
 
  700+ words
... ... Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX(R ... immunogenicity of its cervical cancer candidate vaccine, CERVARIX(R ... evidence that GSK's cervical cancer candidate vaccine demonstrated protection ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Cervarix for protection against cervical ...

  
  South African Medical Journal; 
  July 1, 2007 ;  
  
  
 
  700+ words
... ... GlaxoSmithKline's (GSK) cervical cancer candidate vaccine, Cervarix, demonstrated ... found that GSK's cervical cancer candidate vaccine induced a strong ... study of GSK's cervical cancer candidate vaccine. The study was ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives